Björn Ekwall Memorial Award 2010
Dr Clothier, former Director of the FRAME Alternatives Laboratory (FAL) was presented with the award at a special ceremony at the Kennel Club on Thursday (Nov 4). Richard was a co-founder of the FAL, at the University of Nottingham Medical School, and was its director from 1997 to 2005.
For many years, Richard collaborated with Björn Ekwall on the Multicenter Evaluation of In Vitro Cytotoxicity (MEIC) programme, aimed at the evaluation of the ability of in vitro basal cytotoxicity assays to predict human acute systemic toxicity.
The award recognises his outstanding contributions in the field of in vitro toxicology, and in particular the development, implementation and validation of alternative toxicity test methods. He was presented with it by Prof Ada Kolman of the Björn Ekwall Memorial Fund. He then delivered the memorial lecture entitled "Experience in the Development and Evaluation of In Vitro Alternative Assays".
Dr Clothier has generously donated the award prize money of £1,600 to FRAME.
The full text can be found here.
Over the past 30 years FRAME has, through its Alternatives Laboratory (FAL), developed and participated in the evaluation and validation of alternative in vitro methods. During 20 of those years Dr Richard Clothier was the Director of the FAL, and during this time participated in the development of the criteria and methodology required to validate alternative in vitro methods. It has also become clear that transparency is an important feature of in vitro experimental methods, including data acquisition and analysis.
From the outset of participation in inter-laboratory studies it was considered that human cells should be used in vitro to evaluate potential human adverse reactions.
FRAME has also been aware of the problems that have been raised in terms of in vitro assays, including a) should animal or human cells be used?, b) should primary cells or cell lines be used?, c) should monolayers of 3D models be employed? and d) how and with what should the in vitro data be compared to achieve the best human prediction of adverse effects?
This presentation considers the experiences in the FAL and reflects upon these issues and how FRAME and the FAL have tackled them and learned from them.
Archived November 24